BACKGROUND AND AIMS: Recently, an alternative pathway of tumorigenesis has been identified in the colorectum associated with serrated precursor lesions, variable levels of microsatellite instability (MSI-V), and driven in part by activating mutations in the BRAF proto-oncogene (V599E). Somatic BRAF mutations in hereditary nonpolyposis colon cancer (HNPCC) are rarely observed. Here, we discuss their role in the development of other familial colorectal cancers (CRC). We studied non-FAP, non-HNPCC CRC families characterized by tumors that varied in their level of MSI between individual members. METHODS: A subset of tumors from a total of 55 collected (25 polyps and 30 cancers) from 43 individuals across 11 families underwent pathology review, examination for V599E using allele-specific polymerase chain reaction, and for methylation of the MINT31 CpG island. RESULTS: All MSI-V families met the current revised Bethesda Guidelines and 6 of 11 (55%) met the Amsterdam I criteria. V599E was observed in 12 of 19 (63%) polyps and 14 of 20 (70%) cancers (4 of 4 high MSI, 2 of 4 low MSI, and 8 of 12 stable MSI), a significant increase over HNPCC (0 of 15 or 0%), and unselected CRC (30 of 197 or 15.2%) ( P < .05). Eight of the 10 (80%) cancers that underwent analysis showed hypermethylation of MINT31. CRCs showed early age at onset and were more likely to show a serrated architecture than unselected CRCs ( P < .05). CONCLUSION: These data provide evidence that the families described here represent a syndrome of familial CRC that is distinct from HNPCC. High levels of BRAF mutation and MINT31 hypermethylation suggest an origin in the serrated pathway of CRC development.
BACKGROUND AND AIMS: Recently, an alternative pathway of tumorigenesis has been identified in the colorectum associated with serrated precursor lesions, variable levels of microsatellite instability (MSI-V), and driven in part by activating mutations in the BRAF proto-oncogene (V599E). Somatic BRAF mutations in hereditary nonpolyposis colon cancer (HNPCC) are rarely observed. Here, we discuss their role in the development of other familial colorectal cancers (CRC). We studied non-FAP, non-HNPCC CRC families characterized by tumors that varied in their level of MSI between individual members. METHODS: A subset of tumors from a total of 55 collected (25 polyps and 30 cancers) from 43 individuals across 11 families underwent pathology review, examination for V599E using allele-specific polymerase chain reaction, and for methylation of the MINT31 CpG island. RESULTS: All MSI-V families met the current revised Bethesda Guidelines and 6 of 11 (55%) met the Amsterdam I criteria. V599E was observed in 12 of 19 (63%) polyps and 14 of 20 (70%) cancers (4 of 4 high MSI, 2 of 4 low MSI, and 8 of 12 stable MSI), a significant increase over HNPCC (0 of 15 or 0%), and unselected CRC (30 of 197 or 15.2%) ( P < .05). Eight of the 10 (80%) cancers that underwent analysis showed hypermethylation of MINT31. CRCs showed early age at onset and were more likely to show a serrated architecture than unselected CRCs ( P < .05). CONCLUSION: These data provide evidence that the families described here represent a syndrome of familial CRC that is distinct from HNPCC. High levels of BRAF mutation and MINT31 hypermethylation suggest an origin in the serrated pathway of CRC development.
Authors: A Joan Levine; Aung Ko Win; Daniel D Buchanan; Mark A Jenkins; John A Baron; Joanne P Young; Tiffany I Long; Daniel J Weisenberger; Peter W Laird; Rebecca L McCall; David J Duggan; Robert W Haile Journal: Cancer Prev Res (Phila) Date: 2011-12-05
Authors: Joanne Young; Mark Jenkins; Susan Parry; Bruce Young; Derek Nancarrow; Dallas English; Graham Giles; Jeremy Jass Journal: Gut Date: 2007-06-12 Impact factor: 23.059
Authors: Daniel D Buchanan; Kevin Sweet; Musa Drini; Mark A Jenkins; Aung Ko Win; Michael Gattas; Michael D Walsh; Mark Clendenning; Diane McKeone; Rhiannon Walters; Aedan Roberts; Alasdair Young; Heather Hampel; John L Hopper; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry Phillips; Graeme P Young; Elizabeth Chow; Susan Parry; Sonja Woodall; Kathy Tucker; Amanda Muir; Michael Field; Sian Greening; Steven Gallinger; Jane Green; Michael O Woods; Renee Spaetgens; Albert de la Chapelle; Finlay Macrae; Neal I Walker; Jeremy R Jass; Joanne P Young Journal: Int J Colorectal Dis Date: 2010-03-06 Impact factor: 2.571
Authors: M B Loughrey; P M Waring; A Tan; M Trivett; S Kovalenko; V Beshay; M-A Young; G McArthur; A Boussioutas; A Dobrovic Journal: Fam Cancer Date: 2007-04-24 Impact factor: 2.375